EU hits Illumina with $476M fine for Grail acquisition

Biotech company Illumina was fined $476 million by the European Union for acquiring cancer test company Grail without vetting from the EU, Bloomberg reported July 12.

Advertisement

The fine is about 10 percent of Illumnia’s revenue last year; the company had set aside capital to prepare for the fine. Illumina plans to appeal the decision and described the fine as “disproportionate.” 

Illumina finalized its purchase of Grail in August 2021. In April 2023, the Federal Trade Commission ordered Illumina to divest from Grail.

“If companies merge before our clearance, they breach our rules,” EU Competition Commissioner Margrethe Vestager said. “Illumina and Grail knowingly and deliberately did so by implementing their tie-up as we were still investigating.”

At the Becker's 11th Annual IT + Revenue Cycle Conference: The Future of AI & Digital Health, taking place September 14–17 in Chicago, healthcare executives and digital leaders from across the country will come together to explore how AI, interoperability, cybersecurity, and revenue cycle innovation are transforming care delivery, strengthening financial performance, and driving the next era of digital health. Apply for complimentary registration now.

Download Whitepaper

The cost-saving opportunity most health systems overlook

Many hospitals and health systems scrutinize staffing, service lines, and payer contracts for savings. Fewer look at one of their largest assets: real estate.…

Advertisement

Next Up in Legal & Regulatory Issues

Advertisement

Comments are closed.